Clinical implications of novel activating EGFR mutations in malignant peritoneal mesothelioma

World Journal of Surgical Oncology

Volumn 8, Issue , 2010, Pages

  Foster, Jason M ^a,d   Radhakrishna, Uppala ^a   Govindarajan, Venkatesh ^a   Carreau, Joseph H ^a   Gatalica, Zoran ^b   Sharma, Poonam ^b   Nath, Swapan K ^c   Loggie, Brian W ^a  

^a CREIGHTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b CREIGHTON UNIVERSITY MEDICAL CENTER   (United States)

^c OKLAHOMA CITY UNIVERSITY   (United States)

^d UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE; ERLOTINIB; DNA; PROTEIN KINASE INHIBITOR; QUINAZOLINE DERIVATIVE;

ARTICLE; CANCER GROWTH; CANCER SURVIVAL; CATALYSIS; CLINICAL ARTICLE; HUMAN; HUMAN CELL; HUMAN TISSUE; MISSENSE MUTATION; NUCLEOTIDE SEQUENCE; PERITONEUM MESOTHELIOMA; PROTEIN DOMAIN; PROTEIN EXPRESSION; TREATMENT OUTCOME; COMPARATIVE STUDY; DRUG ANTAGONISM; GENETICS; MESOTHELIOMA; METABOLISM; MUTATION; PERITONEUM TUMOR; POLYMERASE CHAIN REACTION; RETROSPECTIVE STUDY;

DNA, NEOPLASM; HUMANS; MESOTHELIOMA; MUTATION; PERITONEAL NEOPLASMS; POLYMERASE CHAIN REACTION; PROTEIN KINASE INHIBITORS; QUINAZOLINES; RECEPTOR, EPIDERMAL GROWTH FACTOR; RETROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 77957731369     PISSN: None     EISSN: 14777819     Source Type: Journal    
DOI: 10.1186/1477-7819-8-88     Document Type: Article

References (29)

1. Sequist LV, Joshi VA, Janne PA, Bell DW, Fidias P, Lindeman NI, Louis DN, Lee JC, Mark EJ, Longtine J, Verlander P, Kucherlapati R, Meyerson M, Haber DA, Johnson BE, Lynch TJ. Epidermal growth factor receptor mutation testing in the care of lung cancer patients. Clin Cancer Res 2006, 12:4403s-4408s. 10.1158/1078-0432.CCR-06-0099, 16857818.
2. Kosaka T, Yatabe Y, Endoh H, Kuwano H, Takahashi T, Mitsudomi T. Mutations of the epidermal growth factor receptor gene in lung cancer: biological and clinical implications. Cancer Res 2004, 64:8919-8923. 10.1158/0008-5472.CAN-04-2818, 15604253.
3. Lee CM, Lee RJ, Hammond E, Tsodikov A, Dodson M, Zempolich K, Gaffney DK. Expression of HER2neu (c-erbB-2) and epidermal growth factor receptor in cervical cancer: prognostic correlation with clinical characteristics, and comparison of manual and automated imaging analysis. Gynecol Oncol 2004, 93:209-214. 10.1016/j.ygyno.2004.01.006, 15047238.
4. Riviere A, Becker J, Loning T. Comparative investigation of c-erbB2/neu expression in head and neck tumors and mammary cancer. Cancer 1991, 67:2142-2149. 10.1002/1097-0142(19910415)67:8<2142::AID-CNCR2820670823>3.0.CO;2-8, 1672262.
5. Paez JG, Janne PA, Lee JC, Tracy S, Greulich H, Gabriel S, Herman P, Kaye FJ, Lindeman N, Boggon TJ, Naoki K, Sasaki H, Fujii Y, Eck MJ, Sellers WR, Johnson BE, Meyerson M. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 2004, 304:1497-1500. 10.1126/science.1099314, 15118125.
6. Tsao MS, Sakurada A, Cutz JC, Zhu CQ, Kamel-Reid S, Squire J, Lorimer I, Zhang T, Liu N, Daneshmand M, Marrano P, da Cunha Santos G, Lagarde A, Richardson F, Seymour L, Whitehead M, Ding K, Pater J, Shepherd FA. Erlotinib in lung cancer - molecular and clinical predictors of outcome. N Engl J Med 2005, 353:133-144. 10.1056/NEJMoa050736, 16014883.
7. Shepherd FA, Rodrigues Pereira J, Ciuleanu T, Tan EH, Hirsh V, Thongprasert S, Campos D, Maoleekoonpiroj S, Smylie M, Martins R, van Kooten M, Dediu M, Findlay B, Tu D, Johnston D, Bezjak A, Clark G, Santabarbara P, Seymour L. Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med 2005, 353:123-132. 10.1056/NEJMoa050753, 16014882.
8. Lynch TJ, Bell DW, Sordella R, Gurubhagavatula S, Okimoto RA, Brannigan BW, Harris PL, Haserlat SM, Supko JG, Haluska FG, Louis DN, Christiani DC, Settleman J, Haber DA. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 2004, 350:2129-2139. 10.1056/NEJMoa040938, 15118073.
9. Sharma SV, Gajowniczek P, Way IP, Lee DY, Jiang J, Yuza Y, Classon M, Haber DA, Settleman J. A common signaling cascade may underlie "addiction" to the Src, BCR-ABL, and EGF receptor oncogenes. Cancer Cell 2006, 10:425-435. 10.1016/j.ccr.2006.09.014, 2673136, 17097564.
10. Nonaka D, Kusamura S, Baratti D, Casali P, Cabras AD, Younan R, Rosai J, Deraco M. Diffuse malignant mesothelioma of the peritoneum: a clinicopathological study of 35 patients treated locoregionally at a single institution. Cancer 2005, 104:2181-2188. 10.1002/cncr.21239, 16206294.
11. Trupiano JK, Geisinger KR, Willingham MC, Manders P, Zbieranski N, Case D, Levine EA. Diffuse malignant mesothelioma of the peritoneum and pleura, analysis of markers. Mod Pathol 2004, 17:476-481. 10.1038/modpathol.3800067, 14976533.
12. Destro A, Ceresoli GL, Falleni M, Zucali PA, Morenghi E, Bianchi P, Pellegrini C, Cordani N, Vaira V, Alloisio M, Rizzi A, Bosari S, Roncalli M. EGFR overexpression in malignant pleural mesothelioma. An immunohistochemical and molecular study with clinico-pathological correlations. Lung Cancer 2006, 51:207-215. 10.1016/j.lungcan.2005.10.016, 16384623.
13. Eltabbakh GH, Piver MS, Hempling RE, Recio FO, Intengen ME. Clinical picture, response to therapy, and survival of women with diffuse malignant peritoneal mesothelioma. J Surg Oncol 1999, 70:6-12. 10.1002/(SICI)1096-9098(199901)70:1<6::AID-JSO2>3.0.CO;2-X, 9989414.
14. Feldman AL, Libutti SK, Pingpank JF, Bartlett DL, Beresnev TH, Mavroukakis SM, Steinberg SM, Liewehr DJ, Kleiner DE, Alexander HR. Analysis of factors associated with outcome in patients with malignant peritoneal mesothelioma undergoing surgical debulking and intraperitoneal chemotherapy. J Clin Oncol 2003, 21:4560-4567. 10.1200/JCO.2003.04.150, 14673042.
15. Sugarbaker PH, Acherman YI, Gonzalez-Moreno S, Ortega-Perez G, Stuart OA, Marchettini P, Yoo D. Diagnosis and treatment of peritoneal mesothelioma: The Washington Cancer Institute experience. Semin Oncol 2002, 29:51-61. 10.1053/sonc.2002.30236, 11836669.
16. Deraco M, Nonaka D, Baratti D, Casali P, Rosai J, Younan R, Salvatore A, Cabras Ad AD, Kusamura S. Prognostic analysis of clinicopathologic factors in 49 patients with diffuse malignant peritoneal mesothelioma treated with cytoreductive surgery and intraperitoneal hyperthermic perfusion. Ann Surg Oncol 2006, 13:229-237. 10.1245/ASO.2006.03.045, 16444562.
17. Yan TD, Brun EA, Cerruto CA, Haveric N, Chang D, Sugarbaker PH. Prognostic indicators for patients undergoing cytoreductive surgery and perioperative intraperitoneal chemotherapy for diffuse malignant peritoneal mesothelioma. Ann Surg Oncol 2007, 14:41-49. 10.1245/s10434-006-9169-7, 17039392.
18. Sebbag G, Yan H, Shmookler BM, Chang D, Sugarbaker PH. Results of treatment of 33 patients with peritoneal mesothelioma. Br J Surg 2000, 87:1587-1593. 10.1046/j.1365-2168.2000.01571.x, 11091251.
19. Park BJ, Alexander HR, Libutti SK, Wu P, Royalty D, Kranda KC, Bartlett DL. Treatment of primary peritoneal mesothelioma by continuous hyperthermic peritoneal perfusion (CHPP). Ann Surg Oncol 1999, 6:582-590. 10.1007/s10434-999-0582-6, 10493628.
20. Foster JM, Gatalica Z, Lilleberg S, Haynatzki G, Loggie BW. Novel and existing mutations in the tyrosine kinase domain of the epidermal growth factor receptor are predictors of optimal resectability in malignant peritoneal mesothelioma. Ann Surg Oncol 2009, 16:152-158. 10.1245/s10434-008-0206-6, 18998063.
21. Amann J, Kalyankrishna S, Massion PP, Ohm JE, Girard L, Shigematsu H, Peyton M, Juroske D, Huang Y, Stuart Salmon J, Kim YH, Pollack JR, Yanagisawa K, Gazdar A, Minna JD, Kurie JM, Carbone DP. Aberrant epidermal growth factor receptor signaling and enhanced sensitivity to EGFR inhibitors in lung cancer. Cancer Res 2005, 65:226-235.
22. Jackman DM, Yeap BY, Sequist LV, Lindeman N, Holmes AJ, Joshi VA, Bell DW, Huberman MS, Halmos B, Rabin MS, Haber DA, Lynch TJ, Meyerson M, Johnson BE, Janne PA. Exon 19 deletion mutations of epidermal growth factor receptor are associated with prolonged survival in non-small cell lung cancer patients treated with gefitinib or erlotinib. Clin Cancer Res 2006, 12:3908-3914. 10.1158/1078-0432.CCR-06-0462, 16818686.
23. Han SW, Kim TY, Hwang PG, Jeong S, Kim J, Choi IS, Oh DY, Kim JH, Kim DW, Chung DH, Im SA, Kim YT, Lee JS, Heo DS, Bang YJ, Kim NK. Predictive and prognostic impact of epidermal growth factor receptor mutation in non-small-cell lung cancer patients treated with gefitinib. J Clin Oncol 2005, 23:2493-2501. 10.1200/JCO.2005.01.388, 15710947.
24. Mitsudomi T, Kosaka T, Endoh H, Horio Y, Hida T, Mori S, Hatooka S, Shinoda M, Takahashi T, Yatabe Y. Mutations of the epidermal growth factor receptor gene predict prolonged survival after gefitinib treatment in patients with non-small-cell lung cancer with postoperative recurrence. J Clin Oncol 2005, 23:2513-2520. 10.1200/JCO.2005.00.992, 15738541.
25. Yang CH, Yu CJ, Shih JY, Chang YC, Hu FC, Tsai MC, Chen KY, Lin ZZ, Huang CJ, Shun CT, Huang CL, Bean J, Cheng AL, Pao W, Yang PC. Specific EGFR mutations predict treatment outcome of stage IIIB/IV patients with chemotherapy-naive non-small-cell lung cancer receiving first-line gefitinib monotherapy. J Clin Oncol 2008, 26:2745-2753. 10.1200/JCO.2007.15.6695, 18509184.
26. Weinstein IB, Begemann M, Zhou P, Han EK, Sgambato A, Doki Y, Arber N, Ciaparrone M, Yamamoto H. Disorders in cell circuitry associated with multistage carcinogenesis: exploitable targets for cancer prevention and therapy. Clin Cancer Res 1997, 3:2696-2702.
27. Weinstein IB. Cancer. Addiction to oncogenes--the Achilles heal of cancer. Science 2002, 297:63-64. 10.1126/science.1073096, 12098689.
28. Weinstein IB. Disorders in cell circuitry during multistage carcinogenesis: the role of homeostasis. Carcinogenesis 2000, 21:857-864. 10.1093/carcin/21.5.857, 10783304.
29. Govindan R, Kratzke RA, Herndon JE, Niehans GA, Vollmer R, Watson D, Green MR, Kindler HL. Gefitinib in patients with malignant mesothelioma: a phase II study by the Cancer and Leukemia Group B. Clin Cancer Res 2005, 11:2300-2304. 10.1158/1078-0432.CCR-04-1940, 15788680.